Lisa Beth Ferstenberg

Lisa Beth Ferstenberg has spent over 30 years in biopharmaceutical development and has a depth of experience in clinical trials purposed for regulatory submissions and drug approvals. Her areas of specialization include oncology, immunology, vaccines and infectious diseases of global importance, such as tuberculosis, HIV and malaria. She has a particular focus on pharmacovigilance for developing and marketed drugs and has been trained in MedDRA coding of terms. Ferstenberg has held senior executive positions in several early-stage pharmaceutical and biotechnology companies and is a serial entrepreneur with a history of successful fundraising efforts and exits. She also serves as an instructor for the Johns Hopkins University Innovate Program.


Matt Miessau

Matthew Miessau has been an analyst at Epidarex Capital since 2014. He focuses on conducting due diligence on prospective fund investments as well as sourcing and analyzing opportunities for Epidarex’s strategic investors. Miessau is also an instructor at the National Institutes of Health Foundation for Advanced Education in the Sciences, teaching biomedical business development for scientists. 


Mary Ann Shallcross

Mary Ann Shallcross is an instructor for the National Institutes of Health Foundation for Advanced Education in the Sciences graduate course on translation medical product development. She founded and operated MycoMed Technologies, a spinout of Johns Hopkins University that developed diagnostic tests and treatment for pulmonary fungal infections. Shallcross’ broad experience stems from her work at VIRsSYS in gene and immunotherapy and Abbott Laboratories where she held key positions in licensing and acquisitions, strategic planning and product development. During her 10 years at Abbott, she had a proven track record of developing products, assessing technologies, negotiating licenses and launching products for the implementation of corporate growth strategies. Shallcross holds a bachelor’s degree in biological sciences from the University of Chicago and an MBA from Loyola University in Chicago.


Paul Silber

Paul Silber is the founding principal at Blu Venture Investors. He launched and grew the company In Vitro Technologies, Inc. for 15 years before he sold it for $30 million in 2006. He is currently board director or advisor to multiple companies as well as the Biotechnical Institute of Maryland. He also chairs the Greater Baltimore Technology Council’s Biotech Roundtable. Silber holds a Ph.D. in toxicology and is an inventor on five patents.